Journal article · 2024 · Open access

Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators

Philipp Cimiano, Ben Collins, Maria Carmela De Vuono, Thierry Escudier, Juergen Gottowik, Matthias Härtung, Mathias Leddin, Bikalpa Neupane, Raul Rodriguez‐Esteban, Ana Lucía Schmidt, Cornelius Starke-Knäusel, Maarten Voorhaar and 1 more

Frontiers in Medicine, 11, 1274688 · Published 6 March 2024 · DOI 10.3389/fmed.2024.1274688

Open full textCite this paper

In brief

“Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators” is a 2024 journal article by Philipp Cimiano and 12 co-authors, published in Frontiers in Medicine. OpenAlex counts 26 citations as of 22 November 2026, which puts it in the top 6% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Medicine.

Citations
26
Most cited in
2026 (12)
Field-weighted impact
5.51
References
100
Authors
13

Abstract

Patients, life science industry and regulatory authorities are united in their goal to reduce the disease burden of patients by closing remaining unmet needs. Patients have, however, not always been systematically and consistently involved in the drug development process. Recognizing this gap, regulatory bodies worldwide have initiated patient-focused drug development (PFDD) initiatives to foster a more systematic involvement of patients in the drug development process and to ensure that outcomes measured in clinical trials are truly relevant to patients and represent significant improvements to their quality of life. As a source of real-world evidence (RWE), social media has been consistently shown to capture the first-hand, spontaneous and unfiltered disease and treatment experience of patients and is acknowledged as a valid method for generating patient experience data by the Food and Drug Administration (FDA). While social media listening (SML) methods are increasingly applied to many diseases and use cases, a significant piece of uncertainty remains on how evidence derived from social media can be used in the drug development process and how it can impact regulatory decision making, including legal and ethical aspects. In this policy paper, we review the perspectives of three key stakeholder groups on the role of SML in drug development, namely patients, life science companies and regulators. We also carry out a systematic review of current practices and use cases for SML and, in particular, highlight benefits and drawbacks for the use of SML as a way to identify unmet needs of patients. While we find that the stakeholders are strongly aligned regarding the potential of social media for PFDD, we identify key areas in which regulatory guidance is needed to reduce uncertainty regarding the impact of SML as a source of patient experience data that has impact on regulatory decision making.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cimiano, P., Collins, B., De Vuono, M. C., Escudier, T., Gottowik, J., Härtung, M., Leddin, M., Neupane, B., Rodriguez‐Esteban, R., Schmidt, A. L., Starke-Knäusel, C., Voorhaar, M., & Wieckowski, K. (2024). Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators. Frontiers in Medicine, 11, 1274688. https://doi.org/10.3389/fmed.2024.1274688

MLA 9

Cimiano, Philipp, et al. “Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators.” Frontiers in Medicine, vol. 11, 2024, p. 1274688. https://doi.org/10.3389/fmed.2024.1274688.

Chicago

Cimiano, Philipp, Ben Collins, Maria Carmela De Vuono, Thierry Escudier, Juergen Gottowik, Matthias Härtung, Mathias Leddin, et al. 2024. “Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators.” Frontiers in Medicine 11: 1274688. https://doi.org/10.3389/fmed.2024.1274688.

Harvard

Cimiano, P. et al. (2024) ‘Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators’, Frontiers in Medicine, 11, p. 1274688. doi:10.3389/fmed.2024.1274688.

IEEE

P. Cimiano et al., “Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators,” Frontiers in Medicine, vol. 11, p. 1274688, 2024, doi: 10.3389/fmed.2024.1274688.

BibTeX

@article{cimiano2024patient,
  title     = {{Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators}},
  author    = {Cimiano, Philipp and Collins, Ben and De Vuono, Maria Carmela and Escudier, Thierry and Gottowik, Juergen and Härtung, Matthias and Leddin, Mathias and Neupane, Bikalpa and Rodriguez‐Esteban, Raul and Schmidt, Ana Lucía and Starke-Knäusel, Cornelius and Voorhaar, Maarten and Wieckowski, Krzysztof},
  journal   = {Frontiers in Medicine},
  year      = {2024},
  volume    = {11},
  pages     = {1274688},
  doi       = {10.3389/fmed.2024.1274688},
  url       = {https://doi.org/10.3389/fmed.2024.1274688}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202433
20251111
20261212

Its field-weighted citation impact is 5.51: it has been cited 5.51 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions

  • patient-focused drug development
  • social media monitoring
  • real-world evidence
  • patient experience data
  • unmet medical needs
  • regulatory decision-making
  • stakeholder perspectives
  • patient involvement in drug development

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Cimiano, P., Collins, B., De Vuono, M. C., Escudier, T., Gottowik, J., Härtung, M., Leddin, M., Neupane, B., Rodriguez‐Esteban, R., Schmidt, A. L., Starke-Knäusel, C., Voorhaar, M., & Wieckowski, K. (2024). Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators. Frontiers in Medicine, 11, 1274688. https://doi.org/10.3389/fmed.2024.1274688

How many times has this paper been cited?

26 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Medicine: sign in and open the full text from this page.

Who wrote this paper?

Philipp Cimiano, Ben Collins, Maria Carmela De Vuono, Thierry Escudier, Juergen Gottowik, Matthias Härtung, Mathias Leddin, Bikalpa Neupane, Raul Rodriguez‐Esteban, Ana Lucía Schmidt, Cornelius Starke-Knäusel, Maarten Voorhaar and 1 more.

What is the DOI of this paper?

10.3389/fmed.2024.1274688, permanently at https://doi.org/10.3389/fmed.2024.1274688. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.